Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 4
2004 11
2005 20
2006 5
2007 21
2008 21
2009 16
2010 14
2011 18
2012 24
2013 11
2014 10
2015 11
2016 17
2017 24
2018 16
2019 21
2020 15
2021 24
2022 20
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
Trojan A, Roth S, Atassi Z, Kiessling M, Zenhaeusern R, Kadvany Y, Schumacher J, Kullak-Ublick GA, Aapro M, Eniu A. Trojan A, et al. Among authors: aapro m. JMIR Cancer. 2024 Apr 4;10:e54178. doi: 10.2196/54178. JMIR Cancer. 2024. PMID: 38573759 Free PMC article.
Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Gascón P, Harbeck N, Rapoport BL, Anderson R, Brueckmann I, Howe S, Aapro M. Gascón P, et al. Among authors: aapro m. Crit Rev Oncol Hematol. 2024 Apr;196:104306. doi: 10.1016/j.critrevonc.2024.104306. Epub 2024 Feb 23. Crit Rev Oncol Hematol. 2024. PMID: 38401695 Free article. Review.
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Among authors: aapro ms. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):509-519. doi: 10.1080/14737167.2024.2310684. Epub 2024 Feb 12. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38284223
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Among authors: aapro ms. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb;24(2):237-250. doi: 10.1080/14737167.2023.2297926. Epub 2024 Jan 25. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38175140
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
Gligorov J, Benderra MA, Barthere X, de Forceville L, Antoine EC, Cottu PH, Delaloge S, Pierga JY, Belkacemi Y, Houvenaegel G, Pujol P, Rivera S, Spielmann M, Penault-Llorca F, Namer M; et l'ensemble des experts des votes des RPC Saint-Paul 2022-2023. Gligorov J, et al. Bull Cancer. 2023 Nov;110(10S):10S1-10S43. doi: 10.1016/S0007-4551(23)00473-3. Bull Cancer. 2023. PMID: 38061827
287 results